Jazz Pharmaceuticals to acquire Chimerix and its experimental brain cancer drug

Taking stock of the drug industry, from the lab to the medicine chest

March 5, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Jazz Pharmaceuticals to acquire Chimerix and its experimental brain cancer drug The drug, called dordaviprone, has been submitted to the FDA for accelerated approval, with a decision expected by Aug. 18. By Jason Mast STAT+ | To fight U.S. tariffs, Canada should suspend U.S. patents on medicines, one expert argues Canadian law permits the patent commissioner to issue a license to a generic manufacturer and a fee would be paid to the U.S. patent holder. By Ed Silverman Opinion: Global freeloading: Americans shouldn't bear the brunt of drug development costs Other countries enjoy the benefits of American drug innovations, without paying the necessary costs to develop them. By Bobby Jindal and Charlie Katebi Adobe Opinion: Former chairs of the Advisory Committee on Immunization Practices on the panel's role ACIP serves a critical role in reviewing the science to keep Americans healthy and in providing guidance on emerging health threats. By Grace Lee, José Romero, Nancy Bennett, Jonathan Temte, Carol Baker, and Myron Levin

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser